Canopy Growth Corp

TSX:WEED

Earnings Call Analysis

Earnings Call Transcript 2025-Q1

[Operator]

Good morning. My name is [ Showell ]. I will be your conference operator today. I would like to welcome you to Canopy Growth's First Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions].

I will now turn the call over to Tyler Burns, Director, Investor Relations. Tyler, you may begin the conference.

[Tyler Burns, executive]

Good morning, and thank you for joining us. On our call today, we have Canopy Growth's Chief Executive Officer, David Klein; and Chief Financial Officer, Judy Hong. Before financial markets open today, Canopy Growth issued a news release announcing the financial results for our first quarter fiscal year 2025 ended June 30, 2024. The news release and financial statements have been filed on EDGAR and SEDAR and will be available on our website under the Investors tab.

Before we begin, I would like to remind you that our discussion during the call will include forward-looking statements that are based on management's current views and assumptions and that this discussion is qualified in its entirety by the cautionary note regarding forward-looking statements included at the end of the news release issued today. Please review today's earnings release and Canopy's reports filed with the SEC and SEDAR for various factors that could cause actual results to differ materially from projections.

In addition, reconciliations between any non-GAAP measures to their closest reported GAAP measures are included in our earnings release. Please note that all financial information is provided in Canadian dollars unless otherwise stated. Following remarks by David and Judy, we will conduct a question-and-answer session where we will take questions from analysts.

With that, I will turn the call over to David. David, please begin.

[David Klein, executive]

Thanks, Tyler, and good morning, everyone. Thank you for joining us today to discuss Canopy Growth's results for the first quarter of fiscal '25. I'm excited to review the continued progress we've made as an organization, reinforcing our path towards sustained profitability and leadership in the global cannabis market. This quarter demonstrates that our strategic focus is paying off, which is evident in the sustained improvement of our key financial metrics and profitable revenue generation across all of our business units.

During our call, I'll cover three topics. First, our drive to profitability through focus on efficiency in our operations as well as profitable revenue generation over chasing market share at all costs. Second, the well advanced actions within our commercial businesses that set the stage for growth in the second half of fiscal '25. And third, I'll provide an update on the rapid advancement of Canopy USA.

Following my remarks, Judy will review our financial results, including some of the market dynamics we're seeing and the actions we've taken to further strengthen our financial position.

Let's begin with our drive to profitability. In Q1 fiscal '25, Canopy achieved a key profitability milestone. For the first time, thanks to the hard work of all of our teams, all of our business units delivered profitable quarterly adjusted EBITDA. We achieved this through continued work to enhance operational efficiency paired with strong cost management and above all a resolute focus on driving profitable revenue. Against this backdrop, we've generated notable improvements across a range of key financial metrics, including a significant reduction in our overall cost of goods sold down 31% as well as a 24% reduction in SG&A expenses, [indiscernible] are year-over-year.

On the revenue side, our focus on profitable revenue over market share is driving us to direct certain products into the higher-margin channels of Canadian medical and international markets. In part, this contributed to our Canadian medical business delivering its sixth consecutive quarter of growth and record top line within which is arguably the most attractive cannabis segment in Canada. Additionally, this prioritization paired with supply challenges led to a softer top line for our adult-use business for Q1. We've already taken action to address these supply challenges, which we believe related to a strengthened foundation for growth over the coming quarters.

Looking to gross margin. We're pleased with the quarter, including the material improvement in our Canada Cannabis gross margins which increased year-over-year to 32% despite paying close to $9.6 million in excise taxes during the quarter. This improvement drove Canopy's consolidated gross margins up year-over-year to 35% in Q1. Having demonstrated that Canopy can deliver consistent healthy gross margins across all our businesses, our sites are firmly set on driving top line growth.

In Canada, we've made prudent investments to increase both our internal flower and pre-roll joint production capacity. We've also secured additional partnerships across a range of segments to fortify our supply chain. Overall, we expect the higher flower yields from upgrades at our Kincardine facility. Our investment in pre-roll joint production capacity, additional supply agreements and price actions already implemented to help drive stronger top line performance in the coming quarters. Our team is also encouraged by the performance of the broad range of new products that we've delivered to the Canadian adult-use market in the latter half of the first quarter.

This includes 17 new and exciting SKUs. To highlight a few, we've launched two Quebec exclusive flower streams, Tweed and [indiscernible]. Infused pre-rolls from Tweed and 7ACRES. Beverages, including the Tweed Sugar Free Cola and 7ACRES Café Vanilla and unique all-in-one bases from Tweed and 7ACRES with outstanding flavor profiles. We believe the innovation we're bringing to market in addition to the pipeline of NPDs landing later this year will contribute to growth in our Canadian adult-use top line over the coming quarters.

Moving to distribution. Our Canadian cannabis business implemented a new hybrid sales model during the first quarter with a mission to enhance distribution for key brands within our portfolio. This complements our in-house sales capabilities in a cost-efficient manner and has already delivered positive results with distribution increasing 7% sequentially to 61,000 points nationally. We expect these new points of distribution to support stronger brand and top line performance in the second half of fiscal '25.

In our international markets as well as Storz & Bickel, we continue to feel Canopy is well placed for leadership and growth. Backed by surging demand post legalization, Storz & Bickel posted revenue growth of over 100% in Germany within the quarter, which offset a decline in Australia due to the implementation of a regulatory change. Paired with expanding U.S. distribution, we forecast sustained growth for Storz & Bickel in the coming quarters.

Our international markets, in addition to an especially strong quarter in the Polish market, we are highly focused on seizing the opportunity for rapid growth in Germany. In line with our asset-light strategy and to meet the increasing demand for medical cannabis across Europe, actions are underway to augment our Canadian [ grown flower ] with EU-based supply. This preserves Canopy's flexibility, limits the upfront investments required to serve these growing markets and will enable our international markets business to continue delivering robust gross margins.

This work is already well advanced, and we've signed multiple agreements with EU-based flower suppliers to deliver new and exclusive high THC strains to the market. As EU sourced flower comes into our supply chain, we expect strengthened performance in our German medical cannabis business in the latter half of fiscal '25. We also envision that over time our use of EU-based third-party supply will free up more of our Canadian-based supply for use domestically to the benefit of our Canadian business.

Next, I'd like to speak about the rapid advancements that Canopy USA is making and the [ resultant ] growth opportunities. Since our last discussion in May, Canopy USA has closed the acquisitions of Jetty and two of three Wana entities with the full acquisition of Wana expected by the end of summer. In fact, Jetty and Wana are already leveraging a joint sales force to engage retail in New York as the brands of Canopy USA begin to realize opportunities and synergies together.

Focusing further on the performance of each of the Canopy USA entities, Wana has entered Connecticut and New York State, while also launching three new hemp-derived edibles, which opens up a new national customer base. Shifting to the West Coast, Jetty has expanded its solventless vape product offering in California with the launch of a new All-In-One and Hybrid vapes. And as an indication of the strength of this brand, Jetty continues to occupy the #1 position in solventless vapes nationally.

Additionally, following its credit challenges, Acreage is focused on execution across the highest potential states in the U.S. including in the Northeast and Midwest where they hold an incumbent position. As I mentioned on the last call, Acreage's operations are well positioned in Ohio, likely the most exciting U.S. state right now for adult-use cannabis. Botanist dispensaries located in the largest population centers in the state and a Tier 1 cultivation and processing facility with significant expansion potential. This is critical, as despite the slow start to this year due to -- due in large part to their credit challenges, we feel that Acreage is capable of returning to their previous run rate, which saw them generate significant adjusted EBITDA.

I'd like to quickly congratulate the Acreage team on their preparation for the launch of non-medical sales in Ohio, which commenced on Tuesday of this week, and we look forward to seeing their growth in the state. We remain upbeat about Canopy USA and look forward to sharing future updates on this platform as we provide Canopy shareholders with this unique exposure to the U.S. cannabis market.

As we closed the quarter, Canopy stands on a firm foundation, and we're showing progress in every corner of our operations. We have robust core businesses, significantly strengthened financials and a unique strategy for seizing the opportunity of growth in the U.S. via Canopy USA. Our focus remains on leveraging this foundation to achieve multi-market cannabis leadership and we are more prepared than ever to navigate the complexities of the global cannabis market while delivering substantial value to our shareholders and customers.

I'll now turn the call over to Judy, who will discuss our financials in greater detail.

[Judy Hong, executive]

Thank you very much, David, and good morning, everyone. I'll start by reviewing our first quarter fiscal 2025 results. I'll then discuss continued progress we've made on our balance sheet and cash flow, followed by a discussion on our priorities and outlook for the balance of fiscal 2025.

Let's begin with our first quarter results. Q1 FY 2025 demonstrated continued progress in our financial performance, as evidenced by significant year-over-year improvement in gross profit dollars, adjusted EBITDA and free cash flow. Canopy delivers consolidated net revenue of $66 million in Q1, a decrease of 13% or down 3% excluding the impact of divested businesses compared to Q1 of last year. The consolidated gross profit dollars grew 67% year-over-year. Consolidated gross margin in Q1 was 35%. Again, a significant improvement compared to 18% last year. Following a dip in gross margin in Q4, I'm pleased to report our return to solid gross margin performance in Q1, which I'll provide additional details later on the call.

Q1 adjusted EBITDA was a loss of $5 million, an improvement of 77% versus last year. Free cash flow was an outflow of $56 million, an improvement of [ $52 ] million compared to Q1 of last year. Note that we typically incurred negative working capital in the first half of the fiscal year with improvement in the back half due to the timing of certain payments.

I'd like to now review the results of our key businesses in more detail, including progress against our path to profitability. Starting with Canada. Q1 net revenue was $38 million, a decline of 6% compared to a year ago. Canada Medical had another record revenue quarter, increasing 20% compared to last year continuing to benefit from customer mix towards a greater number of insured patients and larger product assortment in the spectrum online store. We're pleased with the outperformance of our Canada Medical, which is also a high-margin business for us.

Our adult-use business was down 22%, which was softer than planned. We continue to be disciplined in the highly competitive adult-use segment in Canada by not chasing market share at all costs. In Q1 revenue was impacted by supply constraints on certain products due in part to lower fulfillment by our CMO partners who are facing financial difficulties. We're working to expand our pool of CMO partners, but given the evolving market dynamics and landscape, it is taking some time to ensure we have [ redundancies ] in play.

With an improved cost structure, we've also taken targeted pricing actions and increased promotions in select categories where we still expect to see good margins. We also launched a number of new products towards the latter part of Q1 with additional new products launching in the fall. All in all, we do expect modest improvement in revenue in Q2 with stronger year-over-year growth in Q3 and Q4 for our Canada cannabis business.

Despite a decline in revenue, Canada gross profit dollars increased to $12 million in Q1 of fiscal '25 versus under $1 million in Q1 of last year. Canada gross margin in Q1 was 32%, and cash gross margin adding back non-cash depreciation costs and [ cost ] was 45%.

Let me provide key drivers of Canada gross margin performance in Q1. First, we continue to see the benefits from cost reduction program that was completed during fiscal 2024, with significant year-over-year reduction in COGS.

Second, the growth in our medical business, which carries higher margins than our adult-use business, also contributed to stronger gross margin performance. During Q1, our medical business accounted for approximately half of revenue in Canada.

Third, Q1 saw improved utilization in our manufacturing operations, which also positively impacted gross margin. We continue to target Canada cash gross margins to be in the mid- to high 30% based on the historical channel mix and are focused on further improving Canada gross margins driven by increase in our cultivation yields in the winter months following installation of new LED lighting at Kincardine in the first half of fiscal '25, strategic sourcing of flower supply at favorable cost and increased throughput in pre-roll production and reduction in labor costs with a new and flexible pre-roll machine now up and running.

International markets cannabis net revenue of $10 million in Q1 and was down 1% compared to Q1 of last year. We saw strong double-digit growth in Europe, notably in Poland which was partially offset by the decline in sales in Australia and U.S. CBD, which we've been winding down ahead of transitioning the business over to Canopy USA.

International markets cannabis gross margin was 36% in Q1 fiscal 2025, up from 34% in Q1 of fiscal '24, driven by a favorable shift in country mix, with higher-margin Poland contributing to a greater portion of sales this year as compared to the prior year period.

Storz & Bickel revenue of $18 million in Q1 was up 2% compared to last year. We saw continued healthy consumer demand for new Venty portable vaporizer that was launched in Q3 of last fiscal year as well as strong sales from its Mighty vaporizer this quarter. Sales increased in many of its key markets, including over 100% growth through the combined B2B and B2C channels in Germany. This was partially offset by a significant decline in shipments to Australia following the recent regulatory change.

We note that Storz & Bickel medical vaporizers, the Mighty Medic, the Mighty Medic Plus and the Volcano Medic are the only whole cannabis vaporizers on the market in Australia. And we believe that this positions Storz & Bickel devices very well in the medical channel of that market. Storz & Bickel gross margin was 40% compared to 43% driven primarily by higher rebates on certain product lines.

Looking at our SG&A expenses for Q1 of fiscal 2025, sales and marketing and G&A expenses declined 24% year-over-year, primarily due to cost reduction program undertaken during fiscal 2024. In Q1 fiscal '25 adjusted EBITDA was a loss of $5 million, an improvement of $18 million compared to a loss of $23 million a year ago. We estimate that our three business units achieved positive adjusted EBITDA with all of the Q1 adjusted EBITDA losses driven by unallocated corporate overhead costs, including public company costs. And as we indicated during our Q4 call, we've identified an additional $10 million to $15 million of cost reduction opportunities mostly in corporate G&A, including savings in professional fees, legal and other public company costs that we expect to realize by the end of fiscal 2025.

I'd like to now review our cash flow and balance sheet. Free cash flow was an outflow of $56 million in Q1, an improvement of 49% compared to the prior year. Cash used from continuing operations was $52 million. This included cash interest payments in the quarter of $18 million, down from $30 million in Q1 of last year. And as expected, we had negative working capital in Q1, driven by timing of certain payments as well as the buildup of bulk flower inventory to ensure supply continuity in Canada. CapEx of $4 million in Q1 was also an increase versus the prior year due to LED lighting investment in Kincardine that will drive improved cultivation yields and lower costs over time.

All in all, we expect free cash outflow to narrow significantly in the second half of fiscal year versus Q1 run rate to reflect the timing of payments and phasing of working capital. Cash flow from investments was an outflow of $33 million in Q1. This included net cash use of $67 million to fund the acquisition of Acreage debt during Q1 and an inflow of $10 million of additional distribution from BioSteel's restructuring process.

Turning to the balance sheet. As of June 30, 2024, we had $195 million in cash and short-term investments and total principal debt balance of $585 million. The principal debt balance declined $40 million in Q1 versus Q4, and the major drivers include reduction of USD 8 million of term loan principal balance resulting from paydown from asset sale proceeds, elimination of CAD 100 million of the promissory note held by constellation and net addition of USD 50 million from the convertible note transaction in May. This morning, we announced an amendment to our credit agreement with the senior secured term loan that extends maturity out to December of 2026, with an option to further extend maturity out to September of 2027.

Pursuant to this agreement, we will be making an initial cash payment of USD 97.5 million to reduce the principal by USD 100 million by December 31, 2024, with an option to pay down additional USD 97.5 million to reduce the principal by $100 million by March 31, 2025. We are pleased to come to this agreement with our lenders that will provide us with cash interest savings and improve balance sheet flexibility.

In early June, we also launched an at-the-market equity offering program of up to USD 250 million. During Q1, we issued 4.7 million shares for total proceeds of CAD 46 million. Subsequent to Q1, we have issued an additional 3.7 million shares for total proceeds of CAD 33 million. Following a significantly reduced debt balance and extended maturity of the term loan, the ATM program provides us with flexibility to invest in strategic growth initiatives.

I'd like to now briefly discuss Canopy USA. This is the first quarter that Canopy USA's financials have been de-consolidated from Canopy Growth's results. And as a result, Canopy's noncontrolling investments in Canopy USA is now presented as equity method investments and in other financial assets on our balance sheet. As David mentioned, Canopy USA is advancing with his acquisition of Wana, Jetty and Acreage. Canopy Growth currently does not have audited financials for the consolidated Canopy USA entities and is not disclosing the financials of each [ entity ] at Canopy USA at this time.

Let me provide some commentary on financial performance of each entity. In the first half of calendar 2024, Acreage has seen revenue and EBITDA decline compared to last year due to its credit challenges. Acreage management is now focused on improving performance in its core markets, including Ohio, where Acreage projects revenue to double by end of calendar 2025 versus [indiscernible].

Wana is also focused on expanding into new states, while maintaining an attractive margin in a highly competitive edibles category. There have been delays in New York and Ohio due to market dynamics and Wana's performance has also been impacted by price compression, retail inventory destocking and SKU rationalization in Colorado. However, trends are expected to improve later this year on the back of New York and Ohio launching. And in addition, as David mentioned, Wana has introduced its hemp-derived offering with its own marketplace website set to launch this month.

Jetty is seeing good underlying momentum for its solventless vape products with expanded offerings. Jetty is currently in the process of also changing distributors in California, which will improve [ route ] to market and lower cost over time. This change is expected to create some noise to its shipments in the near term.

Once Canopy USA closes on its acquisition of Wana and Acreage, and with expected revenue contribution from Ohio's non-medical sales for Acreage, we expect that Canopy USA has the potential to generate annual revenue of upwards of USD 300 million.

I'd like to now provide our key priorities and outlook for the balance of fiscal '25. In Canada Cannabis, we remain focused on driving growth and profitably gaining market share in both the adult-use and medical channels. We expect Q2 to be impacted by continued supply challenges with certain third-party produced products with stronger growth in the back half of this fiscal year, driven by expanded distribution, improved sales velocity and new product launches. In international markets cannabis, we're focused on accelerating growth in Europe, including in our key markets of Germany and Poland, we're focused on ensuring consistent supply of high-quality products as well as launch new products into these markets in the near term.

For Storz & Bickel, we're focused on accelerating growth in the U.S. and other key markets as well as opportunistically expand distribution into new markets. Note that for S&B, Q2 is historically the lowest revenue quarter of the year. And finally, the impact from divested businesses will continue to negatively impact reported sales growth throughout FY '25.

Q2 FY '24 revenue of $69.6 million included approximately $8.3 million of revenues from divested businesses. From a phasing standpoint, we continue to expect stronger year-over-year growth in the second half of our fiscal '25 driven by increased supply and ramp-up of new products as well as lessening impact from divested businesses.

We believe we remain firmly on a path to achieve positive adjusted EBITDA at the consolidated level, inclusive of corporate costs, driven by sales growth, improvement in gross margins and additional G&A savings.

So in closing, we intend to build on the improved financial performance in Q1 and drive profitable growth while continuing to strengthen our financial position over time. This concludes my prepared comments. We'll now take questions.

[Operator]

Thank you, ladies and gentlemen. We will now begin the question-and-answer session.[Operator Instructions]. Your first question comes from Aaron Grey with Alliance Global Partners.

[Aaron Grey, analyst]

So first one for me. You guys have done a lot in terms of cleaning up and simplifying the story in terms of divestitures and with Canopy USA. So as we look forward, Canopy USA, you're waiting for some, I think, audits to be finished where you can consolidate and also for Acreage to close. So just if you can give us some more in terms of the timing, Acreage. I think you said first half of calendar 2025. So just more color in terms of what you're waiting on for that to build to close in terms of -- I think it might be some state approvals or otherwise. And then how we should think about everything built to come in terms of additional disclosure in terms of the financial performance there and when you'll be able to disclose that fully?

[Judy Hong, executive]

Okay. I'll start, Aaron. So from a timing standpoint, as David mentioned, during Q1, Jetty is fully closed. So Canopy USA owns approximately 75% of Jetty at this point. Two of the three entities under Wana have already been closed, and we expect to complete Wana acquisition or Canopy USA expects to complete the Wana acquisition by end of this summer. And then Canopy USA is in the process of acquiring Acreage. So that is really a regulatory process. It's a state-by-state regulatory approval. Our expectation is sometime in the spring of next calendar year, we'll get all of the state approvals required for Canopy USA to complete its acquisition.

In terms of financial disclosure, as we sit here today, Canopy USA obviously has not fully closed all of its entities under Canopy USA. So once we do have Canopy USA fully closing on Wana and Acreage, we would intend to share audited financials and also provide some supplemental financial metrics of Canopy USA, that will likely to be sometime after the Acreage acquisition closes.

[David Klein, executive]

Yes. And Aaron, just to add to that. So all of the -- so the gating item really on closing the final component of Wana as well as Acreage is, in fact, the regulatory approvals at the state level, all of which have been applied for. So now we're just working our way through each state's process, and we'll close as soon as we get all of those approvals in place.

In terms of financial disclosure, Judy outlined in our script just a rough view of what CUSA believes they'll be able to achieve from a top line standpoint. And we believe that you can look at other MSOs to understand EBITDA margins, also keeping in mind that as we're -- as Acreage is operating as a standalone public company. Today, we'll be able to realize a fair amount of public company synergies when that business becomes part of the CUSA platform. So yes, we'll provide detailed financial statements through CUSA as soon as soon as we can, but I think that just provides a good kind of outline as to where that business is today.

[Operator]

Your next question comes from Frederico Gomes with ATB Capital Markets.

[Frederico Yokota Gomes, analyst]

Just on the Canadian Medical Cannabis segment, quite impressive growth there. And sequentially 6 quarters of sequential growth. So can you give a bit more clarity on what's driving that growth? And how much more upside do you think there is to that segment, just given that I think we've seen that the overall market is sort of flat on the medical side in Canada. So how much more growth do you think can come from that segment?

[David Klein, executive]

Yes. So we've had several quarters in a row of growth in that market. We expect that to continue. And it's really coming as a result of strong execution by our medical team. We -- it is a marketplace, so it's not just Canopy products. It's a marketplace with products hand-selected by our team. And we give what we believe is best-in-class service to the participants in that channel. And it's just day in and day out execution on the medical side, that's really driven much of our growth.

[Judy Hong, executive]

Yes. And to your point, Frederico, the market is stagnant to declining just because of the shift into the adult-use channel. But we're gaining market share, as you can see in the numbers, and we think we're well positioned to continue to gain market share with continuation of really offering high-quality products to patients, not just our products but even third-party products that really provide patients with a very broad assortment of offerings.

[Operator]

Your next question comes from Michael Lavery with Piper Sandler.

[Michael Lavery, analyst]

I just wanted to understand the supply dynamics a little better. You said you want to source more EU origin products from third parties. I guess can you just maybe help us understand if that -- if Germany or the broader market there if so is growing and so attractive, who has excess product? And I guess really at what cost? And it seems like that's kind of the place where [ project ] is a little bit more scarce. Is that maybe a misunderstanding.

And then when you talk about freeing up some supply back in Canada, certainly oversupply has long been the problem there, did you overcorrect? Do you need more supply in Canada? How do we just think about both sides of the ocean there?

[David Klein, executive]

No. So Michael, so I'll kind of take it in two points, and I'll start with Canada first. I think in Canada, we have some supply constraints during the quarter that were driven by performance with some of our third-party suppliers, right? And so we're making our supply chain more robust in Canada. And you're right, there is product available However, we just remain focused on when we do a product in the market, we're simply putting it into the higher-margin channels.

As it relates to Europe, there is product available. That's really not the issue in the European channel. And that's available from Canada, but it's also available from end market producers. And so the point of the comments in the script is that over time as we bring on the European producers, we would then free up product out of our Canadian supply chain which would allow us to optimize margin across our total business. And the thing I think that -- the way we're thinking about this is that every single market that has opened up broadly in every geography we've seen start to have supply constrained, then goes along in supply, then prices compress and then people have assets that they don't know how to deal with.

We're actually managing our supply chain in Canada to be an asset-light supply chain. And admittedly, we have some things that we need to do to optimize that asset-light supply chain, but we're all over that. we're thinking about Europe the same way. And so instead of going in heavily with investments, which will potentially compress our margins going forward, we're deploying our strategy into Europe and based on what we're seeing at the moment, we're quite happy with that approach.

[Operator]

Your next question comes from Bill Kirk with ROTH Capital Partners.

[William Kirk, analyst]

Mines is related to the last topic, because margins seem to differ a lot by market, very different margins in each market. So how do you determine where your available supply goes? Like how do you balance that maybe immediate margin potential for some of the sales with the longer-term potential that some markets may have that aren't profitable just yet?

[David Klein, executive]

Yes. I would say, Bill, that's a good question because we haven't interrupted supply into the European markets from Canada, right? So when we say that we're going to allocate to the highest margin areas, we're not doing anything that's choking off supply into Europe and don't intend to do that in the near term, meaning supply coming from Canada. It's within Canada when we're when we -- if we have any sort of supply constraints, we allocate amongst the provinces effectively or the channels, meaning medical versus [ rec ] in Canada, in a way that optimizes for profitability.

So -- and I also want to make sure that the comments that we made in our script too around the [ entity ] that's coming to market is really -- it's not -- it's really just launches of new strains and a few new offerings that we think will be really attractive that we're already getting listings for that will drive revenue growth in Canada later in the year. So I think it's -- the supply allocation is really mostly related to Canada. And then we -- as I said, we have activities underway to improve the supply chain in Canada and make it more robust. And we also have new products coming down the pipeline.

[Judy Hong, executive]

The only add I would have would be just when you look at the flower supply in Canada, we have a bit of a hybrid model, right? So we've got our internal -- internally sourced Kincardine facility and DOJA and then we are looking at partners. So whether it's strategic sourcing of power or -- at this point, I think we're doing a bit more spot buying, and the market is a little bit [ funny ] to be honest. And I think over time, we do think there will be more of the strategic sourcing opportunities that will come online. And really, we're focused on capturing favorable costs so that we can have good margins even from third-party sourced flower across our Canadian adult-use business.

[Operator]

There are no further questions. I will now turn the call over to Mr. Klein for closing remarks.

[David Klein, executive]

Great. Thank you for attending today's conference call. And as you enjoy the rest of the summer, I'd encourage you to try some of our outstanding products from our innovative brands, including beverages like Tweed Sugar Free Cola as well as our new All-In-One vapes from Tweed and 7ACRES. Our Investor Relations team will be available to answer additional questions. Thank you.

[Operator]

This concludes Canopy Growth's First Quarter Fiscal 2025 Financial Results Conference Call. A replay of this conference call will be available until November 7, 2024 and can be accessed following the instructions provided in the company's press release issued earlier today. Thank you for attending today's call.